Literature DB >> 4189290

Controlled trial of amantadine hydrochloride in Parkinson's disease.

J D Parkes, D M Calver, K J Zilkha, R P Knill-Jones.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1970        PMID: 4189290     DOI: 10.1016/s0140-6736(70)90634-3

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  26 in total

1.  On the synchronizing effect of amantadine-1-hydrochlorid (Symmetrel) on pathological EEG-activity.

Authors:  J Vardi; M Streifler
Journal:  J Neural Transm       Date:  1975       Impact factor: 3.575

2.  The clinical use of apomorphine in Parkinson's disease.

Authors:  M J Steiger; N P Quinn; C D Marsden
Journal:  J Neurol       Date:  1992-08       Impact factor: 4.849

Review 3.  The lipophilic bullet hits the targets: medicinal chemistry of adamantane derivatives.

Authors:  Lukas Wanka; Khalid Iqbal; Peter R Schreiner
Journal:  Chem Rev       Date:  2013-02-25       Impact factor: 60.622

4.  Long-term therapy of Parkinson's disease with amantadine, alone and combined with levodopa.

Authors:  L R Zeldowicz; J Hubermann
Journal:  Can Med Assoc J       Date:  1973-10-06       Impact factor: 8.262

5.  Treatment of Parkinson's Disease with levodopa and amantadine used as single drugs and in combined therapy.

Authors:  N Callagham; M Mcllroy; M O'Connor
Journal:  Ir J Med Sci       Date:  1974-03       Impact factor: 1.568

Review 6.  Antiparkinsonian drugs: pharmacological and therapeutic aspects.

Authors:  D B Calne; J L Reid
Journal:  Drugs       Date:  1972       Impact factor: 9.546

7.  Amantadine and the glutamate hypothesis of schizophrenia. Experiences in the treatment of neuroleptic malignant syndrome.

Authors:  J Kornhuber; M Weller
Journal:  J Neural Transm Gen Sect       Date:  1993

Review 8.  Anti-parkinsonian drugs today.

Authors:  N P Quinn
Journal:  Drugs       Date:  1984-09       Impact factor: 9.546

9.  Amantadine-HCl (Symmetrel) in the management of Parkinson's disease: a double-blind cross-over study.

Authors:  A Barbeau; H Mars; M I Botez; M Joubert
Journal:  Can Med Assoc J       Date:  1971-07-10       Impact factor: 8.262

10.  N-methyl-D-aspartate (NMDA) antagonists in Parkinson's disease.

Authors:  J Kornhuber; P Riederer
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-04       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.